{
    "raw_data": {
        "nct_id": "NCT00343668",
        "official_title": "A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy",
        "criteria": {
            "raw_text": "Inclusion Criteria:\n\n* Pathologically proven unresectable adenocarcinoma of stomach\n* With uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan)\n* Age 18 to 70 years old\n* Estimated life expectancy of more than 3 months\n* ECOG performance status of 2 or lower\n* Adequate bone marrow function(absolute neutrophil count \\[ANC\\] ≥1,500/µL, hemoglobin ≥9.0 g/dL,and platelets ≥100,000/µL)\n* Adequate kidney function (serum creatinine \\< 1.5 mg/dL)\n* Adequate liver function (serum total bilirubin \\< 2 times the upper normal limit (UNL); serum transaminases levels \\<3 times \\[\\<5 times for patients with liver metastasis\\] UNL)\n* No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. (but, prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded)\n* No prior radiation therapy for at least 4 weeks before enrollment in the study\n\nExclusion Criteria:\n\n* Other tumor type than adenocarcinoma\n* Central nervous system (CNS) metastases or prior radiation for CNS metastases\n* Gastric outlet obstruction or intestinal obstruction\n* Evidence of gastrointestinal bleeding\n* The patient has bony lesions as the sole evaluable disease.\n* Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri\n* Pregnant or lactating women, women of childbearing potential not employing adequate contraception\n* Other serious illness or medical conditions\n\n  * Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry\n  * History of significant neurologic or psychiatric disorders including dementia or seizures\n  * Active uncontrolled infection\n  * Other serious underlying medical conditions which could impair the ability of the patient to participate in the study\n* Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy\n* concomitant drug medication; The following drugs cause drug interaction with S-1.\n\n  i. Warfarin, phenprocoumon: increase bleeding tendency ii. Increase blood concentration of phenytoin iii. sorivudine: inhibit DPD -\\> increase toxicity according to fluoropyrimidine iv. allopurinol : decrease activity of S-1"
        }
    },
    "structurized": null
}